<DOC>
	<DOCNO>NCT02684422</DOCNO>
	<brief_summary>This study aim examine feature MRSA associate chronic MRSA infection bacterial persistence despite IV antibiotic therapy . Subjects ask expectorate sputum complete CF symptom diary begin end IV therapy .</brief_summary>
	<brief_title>Initial Chronic Methicillin Resistant Staphylococcus Aureus ( MRSA ) Infection Cystic Fibrosis ( CF )</brief_title>
	<detailed_description>This observational , translational study exminined bacterial morphology function pre- vs. post antibiotic therapy patient CF experience pulmonary exacerbation require IV antibiotic . All clinical care dictate treat physician ( ) . Inclusion criterion : 1 . Male female confirm diagnosis CF ( sweat test and/or identification 2 CF disease cause mutation ) . 2 . Chronic infection MRSA define MRSA positive respiratory culture &gt; 1 year &gt; 50 % culture MRSA positive . 3 . Being able expectorate sputum consistent basis , i.e . also end IV therapy 4 . Having pulmonary exacerbation define protocol decision treat physician start IV therapy hospital home . Typically occur &gt; 5 % drop FEV1 % predict compare patient 's baseline increase respiratory symptom . 1 . NOTE : Patients oral inhaled antibiotic without MRSA activity fail i.e . change IV antibiotic allow participate . Exclusion criterion : 1 . Presence / infection B. cepacia genomovar III ( B. cenocepacia ) 2 . Subjects undergone lung liver transplant past ( NOTE : patient list transplant eligible ) 3 . Concomitant participation and/or use investigational drug within 30 day study . Concomitant observational study allow TRI-STAR Sputum collection : The subject ask expectorate sputum sterile specimen cup solely study . This may second sample give one clinical laboratory start therapy . The subject ask repeat sputum sample study end therapy . Time point definition : A ) Start therapy sample : 3 day prior 36 hour first dose anti-MRSA antibiotic . B ) End therapy : earlier 36 hour prior last dose one week completion . Collection clinical information : Clinical information collect include : Demographics , age , CF genotype , anthropometrics ; FEV1 FVC , FEF 25-75 liter % predict per site specific reference value ; medication ( routine start within 2 week time admission/IV therapy ) . CF daily Symptom score : Subject ask complete CF Symptom diary first last 3 day IV therapy . For subject admit hospital administer RC home RC call / e-mail reminder per phone . Spirometry conclusion therapy : Most patient follow-up clinic visit still hospital time completion IV therapy spirometry part routine clinical assessment . NOTE : Patients would clinic visit end therapy may ask return spirometry sputum sample solely study . If subject agrees , reimbursement travel allow . Laboratory Assays : In vitro assay do either bank isolates Aim 1 sputum sample / MRSA isolate sputum include test bacterial fitness growth different condition ; antibiotic susceptibility assay ; metabolic virulence activity gene , mutator rate sputum isolates . More detail provide grant application .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<mesh_term>Staphylococcal Infections</mesh_term>
	<criteria>1 . Male female confirm diagnosis CF ( clinical feature positive sweat test and/or identification 2 CF disease cause mutation ) . 2 . At least 4 year age old . 3 . Chronic infection MRSA define MRSA positive respiratory culture &gt; 1 year â‰¥ 50 % culture MRSA positive e.g . 2/4 recent culture grow MRSA . 4 . Being able expectorate sputum consistent basis , i.e . also end IV therapy . 5 . Having pulmonary exacerbation define protocol decision treat physician start IV therapy hospital home . Typically occur &gt; 5 % drop FEV1 % predict compare patient 's baseline increase respiratory symptom . NOTE : Patients oral inhaled antibiotic without MRSA activity fail outpatient therapy i.e . change IV antiMRSA antibiotic allow participate . ( Example : oral doxycycline admission change ceftaroline = eligible . On oral doxycycline continue admission = eligible ) . Patient enrollment prioritize receive IV vancomycin ceftaroline , secondary consideration patient receive oral antiMRSA therapy ( TMPSMX tetracycline derivative ) initiate hospital admission . Patients linezolid included medication give orally IV may confound analysis . 1 . Presence / infection B. cepacia genomovar III ( =B . cenocepacia ) . Subjects undergone lung liver transplant past ( NOTE : patient list transplant eligible ) 2 . Concomitant participation and/or use investigational drug within 30 day study . 3 . Concomitant observational study allow TRISTAR , approve study investigator proxy .</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>